IBM RXN for Chemistry
Web-based AI platform for retrosynthesis planning and forward reaction prediction — suggests multi-step synthetic routes to target molecules and predicts reaction outcomes from reagents.
What it does
IBM RXN for Chemistry is a web platform that applies AI to two core synthesis tasks: retrosynthesis (working backward from a target molecule to identify feasible synthetic routes) and forward reaction prediction (predicting the product of a reaction given starting materials and reagents). You enter a molecule in SMILES format or draw it using the built-in editor, and the tool proposes routes and reaction conditions ranked by predicted feasibility.
The platform was recently updated with integration of Thieme’s Science of Synthesis database — a curated expert-authored collection covering reaction classes underrepresented in the patent literature that most models train on. IBM Research reports approximately 9× improvement in retrosynthesis prediction accuracy and ~3× improvement in forward prediction following this integration.
Best for
Chemists planning synthetic routes to target molecules, particularly for drug discovery, natural product synthesis, or materials chemistry. Also useful as a first-pass sanity check when evaluating whether a proposed molecule is synthetically feasible before running a de novo design campaign.
Pricing
Freemium. A free tier provides basic retrosynthesis and forward prediction. The full multi-step synthesis planning feature (planning routes up to 40+ steps) and higher-throughput access require a paid account. Institutional licenses available.
Strengths
- End-to-end synthesis planning from a single target molecule — not just one retrosynthetic step but multi-step route proposals
- Forward prediction validates proposed routes: given a reaction you’re planning, it predicts the likely product and flags low-confidence predictions
- Web-based with a molecule drawing editor — no Python required; accessible to researchers without ML infrastructure
- Science of Synthesis integration substantially improved accuracy, especially for reaction classes outside the patent literature mainstream
- Routes can be exported for use in electronic lab notebooks
Limitations
- Training data is biased toward well-documented reaction classes in patents and literature — truly novel or exotic reaction types remain less reliable
- Stereochemistry handling (which face of a molecule a reagent attacks, enantioselectivity) is less reliable than connectivity prediction
- Route proposals are ranked by model confidence, not by practical ease, cost of starting materials, or lab availability — always filter suggested routes through your practical constraints
- A proposed route that the model rates highly still needs expert evaluation and experimental validation before trusting it
How it compares
| vs. | Key difference |
|---|---|
| Molecule.one | Molecule.one focuses more heavily on commercial availability of intermediates and route cost; IBM RXN is broader in reaction type coverage |
| REINVENT 4 | REINVENT 4 is a de novo molecule generator, not a route planner — they address different parts of the drug discovery workflow |
| Chemprop | Chemprop predicts molecular properties (activity, solubility); IBM RXN predicts reactions and routes — complementary, not competing |
| Manual retrosynthesis | AI retrosynthesis is faster for generating candidate routes; expert chemist judgment is still needed to evaluate and select among them |
Related content
- Field Guide: Chemistry
- Glossary: Retrosynthesis, SMILES Notation